Stock MRNA MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
108 USD +1.69% Intraday chart for Moderna, Inc. +6.47% +8.57%
Apr. 24 Sector Update: Health Care Stocks Slipping Late Afternoon MT
Apr. 24 Moderna to Collaborate With OpenAI to Launch New Generation of Medicines MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,518 41,340 102,976 69,006 37,919 41,340 - -
Enterprise Value (EV) 1 5,548 36,842 92,848 59,104 29,315 36,607 37,960 38,019
P/E ratio -12.6 x -53.3 x 8.98 x 8.93 x -8.07 x -14.9 x -20.3 x -60.1 x
Yield - - - - - - - -
Capitalization / Revenue 108 x 51.5 x 5.58 x 3.58 x 5.54 x 9.82 x 8.56 x 6.44 x
EV / Revenue 92.1 x 45.9 x 5.03 x 3.07 x 4.28 x 8.7 x 7.86 x 5.93 x
EV / EBITDA -10.8 x -50.3 x 6.86 x 6.05 x -8.1 x -13 x -17.9 x -50.9 x
EV / FCF -11.3 x 18.8 x 6.96 x 12.9 x -7.66 x -13.5 x -20.1 x -62.7 x
FCF Yield -8.84% 5.32% 14.4% 7.75% -13% -7.41% -4.98% -1.6%
Price to Book 6.14 x 16.3 x 7.24 x 3.7 x 2.74 x 3.53 x 4.69 x 5.39 x
Nbr of stocks (in thousands) 333,250 395,710 405,450 384,180 381,284 382,880 - -
Reference price 2 19.56 104.5 254.0 179.6 99.45 108.0 108.0 108.0
Announcement Date 2/26/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 60.21 803.4 18,471 19,263 6,848 4,210 4,829 6,415
EBITDA 1 -514.7 -731.9 13,528 9,768 -3,618 -2,824 -2,117 -747.3
EBIT 1 -545.7 -763.1 13,296 9,420 -4,239 -3,070 -2,303 -958.5
Operating Margin -906.38% -94.99% 71.98% 48.9% -61.9% -72.93% -47.7% -14.94%
Earnings before Tax (EBT) 1 -514.7 -744.5 13,285 9,575 -3,942 -2,772 -1,942 -353
Net income 1 -514 -747.1 12,202 8,362 -4,714 -2,807 -2,080 -737.1
Net margin -853.73% -92.99% 66.06% 43.41% -68.84% -66.68% -43.08% -11.49%
EPS 2 -1.550 -1.960 28.29 20.12 -12.33 -7.248 -5.310 -1.797
Free Cash Flow 1 -490.5 1,960 13,336 4,581 -3,825 -2,711 -1,891 -606.8
FCF margin -814.7% 243.91% 72.2% 23.78% -55.86% -64.41% -39.16% -9.46%
FCF Conversion (EBITDA) - - 98.58% 46.9% - - - -
FCF Conversion (Net income) - - 109.29% 54.78% - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/26/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 4,969 7,211 6,066 4,749 3,364 5,084 1,862 344 1,831 2,811 125.3 72.22 1,584 2,428 632.6
EBITDA - 5,488 - - - - - - - 208 - - - - -
EBIT 1 3,558 5,410 4,227 2,447 1,166 1,580 -366 -1,867 -2,012 6 -1,412 -1,393 -374.7 169.4 -976.6
Operating Margin 71.6% 75.02% 69.68% 51.53% 34.66% 31.08% -19.66% -542.73% -109.89% 0.21% -1,126.94% -1,929.48% -23.65% 6.98% -154.39%
Earnings before Tax (EBT) 1 3,552 5,410 4,229 2,474 1,217 1,655 -305 -1,749 -1,958 70 -1,338 -1,340 -314.6 212.6 -818.7
Net income 1 3,333 4,868 3,657 2,197 1,043 1,465 79 -1,380 -3,630 217 -1,387 -1,371 -362.6 275.3 -818.7
Net margin 67.08% 67.51% 60.29% 46.26% 31% 28.82% 4.24% -401.16% -198.25% 7.72% -1,106.73% -1,898.82% -22.89% 11.34% -129.42%
EPS 2 7.700 11.29 8.580 5.240 2.530 3.610 0.1900 -3.620 -9.530 0.5500 -3.572 -3.529 -0.8781 0.5977 -2.562
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/24/22 5/4/22 8/3/22 11/3/22 2/23/23 5/4/23 8/3/23 11/2/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 971 4,498 10,128 9,902 8,604 4,733 3,380 3,320
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -491 1,960 13,336 4,581 -3,825 -2,711 -1,891 -607
ROE (net income / shareholders' equity) -38% -40% 146% 50.3% -28.6% -22.7% -20.3% -9.08%
ROA (Net income/ Total Assets) -28.9% -16.7% 76.2% 33.1% -21.3% -16.5% -14.3% -12.5%
Assets 1 1,776 4,463 16,003 25,264 22,142 17,010 14,558 5,920
Book Value Per Share 2 3.190 6.420 35.10 48.50 36.30 30.60 23.00 20.00
Cash Flow per Share 2 - 5.320 31.60 12.00 -8.160 -6.090 -3.110 2.080
Capex 1 31.6 67.4 284 400 707 902 461 399
Capex / Sales 52.41% 8.4% 1.54% 2.08% 10.32% 21.42% 9.56% 6.22%
Announcement Date 2/26/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
108 USD
Average target price
134.3 USD
Spread / Average Target
+24.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Financials Moderna, Inc.